case_images: PMC11739454_01
case_images: Histopathological findings of the transbronchial lung biopsy specimen of the lung tumor. Hematoxylin and eosin staining (x20) showing adenocarcinoma.
case_images: TCA-16-e15508-g002.jpg
case_images: PMC11739454_01_TCA-16-e15508-g002.jpg
case_images: tca15508-fig-0001
case_images: Transbronchial lung biopsy confirmed adenocarcinoma (Figure 1), resulting in cT4N1M1c stage IVB lung adenocarcinoma diagnosis.
case_images: Patient's treatment course. CDDP, cisplatin; nab-PTX, nab-paclitaxel; NGS, next-generation sequencing; PEM, pemetrexed; Pembro, pembrolizumab.
case_images: TCA-16-e15508-g004.jpg
case_images: PMC11739454_01_TCA-16-e15508-g004.jpg
case_images: tca15508-fig-0002
case_images: Figure 2 shows the patient's treatment course.
case_images: Computed tomography (CT) scan of primary lung lesion and liver metastasis before and after tepotinib treatment. (a, d) CT images before treatment showed masses in the upper lobe of the left lung (arrow) and liver (arrowhead). (b, e) CT images showing shrinkage of both pulmonary and hepatic lesions 3 months after tepotinib treatment initiation. (c, f) CT images revealing no recurrence of lung lesions and an enlarged hepatic lesion 8 months after tepotinib treatment initiation.
case_images: TCA-16-e15508-g003.jpg
case_images: PMC11739454_01_TCA-16-e15508-g003.jpg
case_images: tca15508-fig-0003
case_images: Tumors decreased in size after tepotinib initiation (-30.9%), with a partial response (PR) after 5 months of treatment (Figure 3).